Yervoy Patent Status and Expiry Timeline
Yervoy (ipilimumab), Bristol Myers Squibb's CTLA-4 inhibitor for melanoma and other cancers, has multiple patents listed in the FDA's Orange Book. Key composition-of-matter patents expired in 2024 in the US (e.g., US 6,682,736), but formulation, method-of-use, and process patents extend protection into the 2030s.[1] For instance, US 8,691,954 (dosing regimen) runs until 2031, with pediatric exclusivity pushing some to 2032. No generic or biosimilar approvals are imminent; the first potential US biosimilar could launch post-2032 amid ongoing litigation.[1][2]
Impact of Expiry on Pricing and Access
Patent expiry alone won't deliver immediate or significant cost relief. Yervoy's list price exceeds $170,000 per course, driven by branded pricing, lack of competition, and high demand in immunotherapy combos (e.g., with Opdivo).[3] Even after core patents lapse, secondary patents and 12-year biologics exclusivity (expired 2023 for initial approval) block generics. Biosimilars, requiring FDA interchangeability studies, face 5-7 year delays post-patent cliffs, as seen with Herceptin (first biosimilar 7 years after expiry).[1] Expect modest 20-30% initial discounts from biosimilars, not the 80%+ drops for small-molecule generics.
Biosimilar Pipeline and Entry Barriers
At least five Yervoy biosimilars are in development: Formycon/Bioeq (Phase 3 complete, targeting 2028 EU launch), Intas, and Alkem in India targeting earlier local entry.[1][4] US entry hinges on winning patent challenges—BMS has settled some (e.g., with Samsung Bioepis) for delayed launches post-2032. High manufacturing complexity for monoclonal antibodies raises biosimilar costs, limiting aggressive undercutting. EU expiry in 2025 may pressure US prices indirectly via global arbitrage.
Comparison to Other Immunotherapies
Unlike small-molecule drugs with sharp post-patent drops (e.g., Revlimid generics at 90% off), biologics like Yervoy see slower relief:
| Drug | Key Patent Expiry | First Biosimilar Launch | Price Drop |
|------|-------------------|-------------------------|------------|
| Yervoy | 2031-2032 (US) | ~2033+ | 20-40% initially[1] |
| Keytruda | 2028 (US) | 2030+ | Projected 25-50%[5] |
| Opdivo | 2028-2035 | 2030+ | Similar trajectory[1] |
| Herceptin | 2019 | 2020 | ~35% by 2022[6] |
Real-world relief depends on payer negotiations; Medicare caps at $2,000/month post-2026 may already curb costs more than expiry.[3]
Factors Limiting Cost Relief
- Litigation Risks: BMS enforces evergreening patents; 80% of biologics face Paragraph IV challenges delaying entry 2-4 years.[1]
- Market Dynamics: Yervoy's $2B+ annual sales fund defenses; combo use with patented Opdivo ties pricing.[2]
- Patient Access: Discounts via BMS assistance (up to 100% copay) already help insured patients; uninsured face full brunt until biosimilars scale.
- Global Variations: India generics available now at 70% less, but US import restrictions apply.[4]
Expiry erodes monopoly pricing gradually, but significant relief—defined as 50%+ drops—likely waits until 2035+ with multiple competitors.
Sources:
[1]: DrugPatentWatch.com - Yervoy Patents
[2]: FDA Orange Book, accessed 2024
[3]: IQVIA National Sales Perspectives, 2023
[4]: GaBI Online Biosimilar Pipeline Tracker
[5]: Evaluate Pharma World Preview 2024
[6]: CMS Medicare Part B Spending Data